Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats

Rationale and objectivesBehavioral, neurochemical and pharmaco-EEG profiles of a new synthetic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats were examined.Materials and methodsLocomotor effects, prepulse inhibition (PPI) of acoustic startle reaction (ASR), dopamine and its metabolite levels in nucleus accumbens (NAc), EEG power spectra and coherence in freely moving rats were analysed. Amphetamine was used as a reference compound.Results2C-B had a biphasic effect on locomotion with initial inhibitory followed by excitatory effect; amphetamine induced only hyperlocomotion. Both drugs induced deficits in the PPI; however they had opposite effects on ASR. 2C-B increased dopamine but decreased 3,4-dihydroxyphenylacetic acid (DOPAC) in the NAc. Low doses of 2C-B induced a decrease in EEG power spectra and coherence. On the contrary, high dose of 2C-B 50 mg/kg had a temporally biphasic effect with an initial decrease followed by an increase in EEG power; decrease as well as increase in EEG coherence was observed. Amphetamine mainly induced an increase in EEG power and coherence in theta and alpha bands. Increases in the theta and alpha power and coherence in 2C-B and amphetamine were temporally linked to an increase in locomotor activity and DA levels in NAc.Conclusions2C-B is a centrally active compound similar to other hallucinogens, entactogens and stimulants. Increased dopamine and decreased DOPAC in the NAc may reflect its psychotomimetic and addictive potential and monoaminoxidase inhibition. Alterations in brain functional connectivity reflected the behavioral and neurochemical changes produced by the drug; a correlation between EEG changes and locomotor behavior was observed.

[1]  N. Swerdlow,et al.  Amphetamine Effects on Prepulse Inhibition Across-Species: Replication and Parametric Extension , 2003, Neuropsychopharmacology.

[2]  G. Baker,et al.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine , 1995, Psychopharmacology.

[3]  M. Balíková,et al.  Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. , 2008, Toxicology letters.

[4]  A. Rechtschaffen,et al.  Sleep deprivation in the rat: III. Total sleep deprivation. , 1989, Sleep.

[5]  I. Bosman,et al.  A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs , 2004, Pharmacy World and Science.

[6]  J. Horáček,et al.  An analysis of spontaneous behavior following acute MDMA treatment in male and female rats. , 2007, Neuro endocrinology letters.

[7]  V. Vyazovskiy,et al.  Running wheel accessibility affects the regional electroencephalogram during sleep in mice. , 2006, Cerebral cortex.

[8]  R. Thisted,et al.  Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis , 2005, Psychopharmacology.

[9]  Marie Balíková,et al.  Electroencephalographic Spectral and Coherence Analysis of Ketamine in Rats: Correlation with Behavioral Effects and Pharmacokinetics , 2011, Neuropsychobiology.

[10]  P. Moya,et al.  Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  A. Shulgin,et al.  Centrally active phenethylamines. , 1975, Psychopharmacology communications.

[12]  I. Bosman,et al.  More data about the new psychoactive drug 2C-B. , 1999, Journal of Analytical Toxicology.

[13]  R. de la Torre,et al.  3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. , 2001, Chemical research in toxicology.

[14]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[15]  J. Gotman,et al.  High-frequency γ electroencephalogram activity in association with sleep-wake states and spontaneous behaviors in the rat , 1997, Neuroscience.

[16]  S. Consolo,et al.  Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study , 1999, Psychopharmacology.

[17]  A. Malhotra,et al.  Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.

[18]  D. Nichols,et al.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.

[19]  I Tobler,et al.  Interhemispheric coherence of the sleep electroencephalogram in mice with congenital callosal dysgenesis , 2004, Neuroscience.

[20]  M. Balíková,et al.  Studies on distribution of para-methoxymethamphetamine (PMMA) designer drug in rats using gas chromatography-mass spectrometry. , 2009, Legal medicine.

[21]  F. Carvalho,et al.  Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  M. Hascöet,et al.  Animal models of anxiety in mice , 2007, Fundamental & clinical pharmacology.

[23]  J. Pilcher,et al.  Sleep deprivation in the rat: IX. Recovery. , 1989, Sleep.

[24]  G. Carey,et al.  Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. , 2001, European journal of pharmacology.

[25]  T. Páleníček,et al.  Relation of sex and estrous phase to deficits in prepulse inhibition of the startle response induced by ecstasy (MDMA) , 2005, Behavioural pharmacology.

[26]  G. Young.  Relationship between amphetamine-induced effects on EEG power spectra and motor activity in rats , 1988, Pharmacology Biochemistry and Behavior.

[27]  K. Tsujikawa,et al.  A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. , 2005, Forensic science international.

[28]  A. Shulgin,et al.  PIHKAL: A Chemical Love Story , 1991 .

[29]  M. Geyer,et al.  Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. , 1989, NIDA research monograph.

[30]  W. Dimpfel,et al.  Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG) , 2004, Psychopharmacology.

[31]  M. Geyer,et al.  The role of 5-HT(1A) receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats. , 1996, Behavioural pharmacology.

[32]  B. Yamamoto,et al.  Acute and subchronic effects of methylenedioxymethamphetamine [(±)MDMA] on locomotion and serotonin syndrome behavior in the rat , 1989, Pharmacology Biochemistry and Behavior.

[33]  M. Farré,et al.  4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects , 2012, Journal of psychopharmacology.

[34]  P. Riederer,et al.  A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease , 2004, Neurology.

[35]  M. Balíková,et al.  Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. , 2007, Forensic science international.

[36]  N. Swerdlow,et al.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review , 2001, Psychopharmacology.

[37]  N. V. Barbosa,et al.  Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice , 2011, Behavioural pharmacology.

[38]  G. Buzsáki,et al.  A neural coding scheme formed by the combined function of gamma and theta oscillations. , 2008, Schizophrenia bulletin.

[39]  J C Shaw,et al.  The EEG as a Measure of Cerebral Functional Organization , 1977, British Journal of Psychiatry.

[40]  R. Thatcher,et al.  Human cerebral hemispheres develop at different rates and ages. , 1987, Science.

[41]  M. Koch,et al.  The acoustic startle response in rats—circuits mediating evocation, inhibition and potentiation , 1997, Behavioural Brain Research.

[42]  Jose C. Principe,et al.  Design and Implementation of Linear Phase FIR Filters for Biological Signal Processing , 1986, IEEE Transactions on Biomedical Engineering.

[43]  R. Thatcher,et al.  Cortico-cortical associations and EEG coherence: a two-compartmental model. , 1986, Electroencephalography and clinical neurophysiology.

[44]  R. Šlamberová,et al.  Monitoring of dopamine and its metabolites in brain microdialysates: method combining freeze-drying with liquid chromatography-tandem mass spectrometry. , 2011, Journal of chromatography. A.

[45]  Bryan Kolb,et al.  Analysis of Behavior in Laboratory Rodents , 1999 .

[46]  M. Hascöet,et al.  Anxiolytic-like effect of 5-HT2 ligands and benzodiazepines co-administration: Comparison of two animal models of anxiety (the four-plate test and the elevated plus maze) , 2007, Behavioural Brain Research.

[47]  R. Glennon,et al.  A preliminary investigation of the psychoactive agent 4-Bromo-2,5-Dimethoxyphenethylamine: A potential drug of abuse , 1988, Pharmacology Biochemistry and Behavior.

[48]  A. Kalgutkar,et al.  Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. , 2001, Chemical research in toxicology.

[49]  M. Geyer.  Behavioral Studies of Hallucinogenic Drugs in Animals: Implications for Schizophrenia Research , 1998, Pharmacopsychiatry.

[50]  Michael Davis,et al.  Psilocybin: Biphasic dose-response effects on the acoustic startle reflex in the rat , 1977, Pharmacology Biochemistry and Behavior.

[51]  J Lát,et al.  The analysis of habituation. , 1973, Acta neurobiologiae experimentalis.

[52]  Giulio Tononi,et al.  Total Sleep Deprivation , 2004 .

[53]  A. Deutch,et al.  Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell , 1992, Neuroscience.

[54]  S. M. Owens,et al.  (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration , 2004, Pharmacology Biochemistry and Behavior.

[55]  M. Geyer,et al.  A characteristic effect of hallucinogens on investigatory responding in rats , 1979, Psychopharmacology.

[56]  N. Swerdlow,et al.  Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges , 2001, Psychopharmacology.

[57]  B. Pitt.  Psychopharmacology , 1968, Mental Health.

[58]  J. Horáček,et al.  Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose , 2007, Psychopharmacology.

[59]  P. Moya,et al.  Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5‐HT2A and 5‐HT2C receptors , 2002, British journal of pharmacology.

[60]  T. Joh,et al.  Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization , 1997, Synapse.

[61]  S. Smolinske,et al.  Foxy methoxy: A new drug of abuse , 2005, Journal of Medical Toxicology.

[62]  R A Levitt,et al.  Sleep Deprivation in the Rat , 1966, Science.

[63]  I. Bosman,et al.  Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. , 2001, Forensic science international.

[64]  L. Spear,et al.  Effects of acute ethanol or amphetamine administration on the acoustic startle response and prepulse inhibition in adolescent and adult rats , 2006, Psychopharmacology.

[65]  A. Rechtschaffen,et al.  Effects of method, duration, and sleep stage on rebounds from sleep deprivation in the rat. , 1999, Sleep.

[66]  D. Marona-Lewicka,et al.  Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action , 2007, Pharmacology Biochemistry and Behavior.

[67]  J. Ison,et al.  Effects of motor activity on the elicitation and modification of the startle reflex in rats , 1986 .

[68]  J. Horáček,et al.  Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[69]  Martin P Paulus,et al.  Effects of Hallucinogens on Locomotor and Investigatory Activity and Patterns: Influence of 5-HT2A and 5-HT2C Receptors , 1998, Neuropsychopharmacology.

[70]  M. Bossong,et al.  Methylone and mCPP, two new drugs of abuse? , 2005, Addiction biology.

[71]  Robert W Thatcher,et al.  Quantitative EEG and the Frye and Daubert Standards of Admissibility , 2003, Clinical EEG.

[72]  Peter Vontobel,et al.  5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride , 1999, Neuropsychopharmacology.

[73]  M. Davis,et al.  Mescaline: excitatory effects on acoustic startle are blocked by serotonin2 antagonists , 2004, Psychopharmacology.

[74]  J. Horáček,et al.  Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats , 2011, Pharmacology Biochemistry and Behavior.

[75]  F. Oesch,et al.  Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. , 2005, Toxicology.

[76]  D. Nutt,et al.  Neurobiology of addiction and implications for treatment , 2003, British Journal of Psychiatry.

[77]  G. Di Chiara,et al.  Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[78]  M. Brazier,et al.  Architectonics of the cerebral cortex , 1978 .

[79]  M. Hascöet,et al.  Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT2A/2C agonist) in the four-plate test in mice , 2007, European Neuropsychopharmacology.

[80]  M. Geyer,et al.  LSD-induced alterations of locomotor patterns and exploration in rats , 2004, Psychopharmacology.

[81]  C. Gambelunghe,et al.  Sleep-wake variables and EEG power spectra in Mongolian gerbils and Wistar rats , 1994, Physiology & Behavior.

[82]  M. Geyer,et al.  The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[83]  M. Bronson,et al.  A behavioral comparison of Nexus, cathinone, BDB, and MDA , 1995, Pharmacology Biochemistry and Behavior.

[84]  G. Koob,et al.  The Neurobiology of Addiction , 1997, Alcohol health and research world.

[85]  M. Cole,et al.  4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. , 2002, Science & justice : journal of the Forensic Science Society.

[86]  J. Horáček,et al.  Increased sensitivity to the acute effects of MDMA (“ecstasy”) in female rats , 2005, Physiology & Behavior.

[87]  B. Cassels,et al.  The action of the psychoactive drug 2C-B on isolated rat thoracic aorta. , 1992, General pharmacology.

[88]  N. Swerdlow,et al.  Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. , 2000, Behavioural pharmacology.

[89]  M. Koch,et al.  The neurobiology of startle , 1999, Progress in Neurobiology.

[90]  Alteration of behavior in mice by muscimol is associated with regional electroencephalogram synchronization , 2007, Neuroscience.